MedTrace Logo

Recombinant Human Prolactin for Lactation Induction

NCT00181610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-01-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).

Conditions

  • Lactation

Interventions

DRUG

Recombinant Human Prolactin

60 mcg/kg every 12 hours

BIOLOGICAL

Recombinant human prolactin

60 mcg/kg given every 12 hours or every 24 hours

BIOLOGICAL

Normal Saline

twice per day

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Corrine K Welt, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00181610 on ClinicalTrials.gov